First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine

  title={First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine},
  author={C. Keech and G. Albert and P. Reed and S. Neal and J. Plested and M. Zhu and S. Cloney-Clark and H. Zhou and N. Patel and M. Frieman and R. Haupt and J. Logue and M. McGrath and S. Weston and P. Piedra and I. Cho and A. Robertson and C. Desai and K. Callahan and M. Lewis and P. Price-Abbott and N. Formica and V. Shinde and L. Fries and J. D. Linkliter and P. Griffin and B. Wilkinson and G. Smith and G. Glenn},
  • C. Keech, G. Albert, +26 authors G. Glenn
  • Published 2020
  • Medicine
  • medRxiv
  • Background NVX-CoV2373 is a recombinant nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins. We present the Day 35 primary analysis of our trial of NVX-CoV2373 with or without the saponin-based Matrix-M1 adjuvant in healthy adults. Methods This is a randomized, observer-blinded, placebo-controlled, phase 1 trial in 131 healthy adults. Trial vaccination comprised two intramuscular injections, 21 days apart. Primary outcomes were reactogenicity, safety labs, and… CONTINUE READING
    12 Citations
    Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2
    • 15
    • PDF
    NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge
    • 8
    • PDF
    SARS-CoV-2 vaccines in development
    • 34
    • PDF
    Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines
    Self-assembling nanoparticles presenting receptor binding domain and stabilized spike as next-generation COVID-19 vaccines
    • 1
    • PDF


    SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses
    • 9
    • PDF
    SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice
    • 23
    • PDF
    The spike protein of SARS-CoV — a target for vaccine and therapeutic development
    • 602
    • PDF
    A Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein (EBOV GP) Nanoparticle Vaccine with Matrix-M™ Adjuvant in Healthy Adults.
    • 5
    • PDF
    Effectiveness of convalescent plasma therapy in severe COVID-19 patients
    • 690
    • PDF